Group Ii, Lp Column Group I... Net Worth

The estimated Net Worth of Group Ii, Lp Column Group I... is at least $13.5 Million dollars as of 25 May 2022. Group I owns over 1,900 units of RAPT Therapeutics stock worth over $81,425 and over the last 3 years Group sold RAPT stock worth over $13,406,485.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Group I RAPT stock SEC Form 4 insiders trading

Group has made over 8 trades of the RAPT Therapeutics stock since 2021, according to the Form 4 filled with the SEC. Most recently Group bought 1,900 units of RAPT stock worth $23,655 on 25 May 2022.

The largest trade Group's ever made was buying 1,250,000 units of RAPT Therapeutics stock on 10 May 2022 worth over $13,337,500. On average, Group trades about 185,506 units every 31 days since 2021. As of 25 May 2022 Group still owns at least 42,189 units of RAPT Therapeutics stock.

You can see the complete history of Group I stock trades at the bottom of the page.

Insiders trading at RAPT Therapeutics

Over the last 5 years, insiders at RAPT Therapeutics have traded over $79,325,123 worth of RAPT Therapeutics stock and bought 4,298,405 units worth $48,553,258 . The most active insiders traders include Peter Svennilson, David V Goeddel, and Fund L.P.Topspin Biotech Fu.... On average, RAPT Therapeutics executives and independent directors trade stock every 11 days with the average trade being worth of $127,774. The most recent stock trade was executed by Dirk G. Brockstedt on 5 January 2024, trading 898 units of RAPT stock currently worth $20,456.

What does RAPT Therapeutics do?

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead oncology drug candidate is FLX475, an oral small molecule C-C motif chemokine receptor 4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company's lead inflammation drug candidate is RPT193 to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. It is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1 that are in the discovery stage of development. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Complete history of Group I stock trades at RAPT Therapeutics

RAPT Therapeutics executives and stock owners

RAPT Therapeutics executives and other stock owners filed with the SEC include:

• Rodney Young,
  Chief Financial Officer
• Brian Wong,
  President, Chief Executive Officer, Director
• Dirk Brockstedt,
  Chief Scientific Officer
• Dr. Brian Russell Wong M.D., Ph.D.,
  CEO, Pres & Director
• Dr. William Ho,
  Chief Medical Officer
• Dr. Dirk G. Brockstedt Ph.D.,
  Chief Scientific Officer
• Mary Gray,
  Independent Director
• Wendye Robbins,
  Independent Director
• William Rieflin,
  Independent Director
• Linda Kozick,
  Independent Director
• Michael Giordano,
  Independent Director
• Peter Svennilson,
  Director
• William Ho,
  Chief Medical Officer
• Lisa Moore,
  Vice President - Business Development and Strategy
• Phyllis Gray,
  Vice President of Human Resources
• Paul Kassner,
  Senior Vice President - Quantitative and Computational Biology
• Dr. David Wustrow,
  Sr. VP of Drug Discovery & Preclinical Devel.
• Dr. Paul Kassner,
  Sr. VP of Quantitative & Computational Biology
• Steve Young Ph.D.,
  VP of Technology
• Rodney K. B. Young,
  CFO, Principal Accounting Officer & Sec.
• Group Ii, Lp Column Group I...,
  
• Group Ii, Lp Column Group I...,
  
• Perkins Caufield & Byers Xv...,
  
• David V Goeddel,
  Director
• Group Ii, Lp Column Group I...,
  
• Group Ii, Lp Column Group I...,
  
• Group Ii, Lp Column Group I...,
  
• Fund L.P.Topspin Biotech Fu...,
  
• Karen C Lam,
  VP, Finance and Controller
• Lori Lyons Williams,